Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 13/20 | 0.75 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | WNK1 | Q9H4A3 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114477 | 1.00 | MLNR (0.75) | MLNRMGLLWNK1LMNAKMT2A | |
| SCHEMBL2767313 | 0.91 | MLNR (0.61) | MLNRMGLL | |
| SCHEMBL5107890 | 0.91 | MLNR (0.61) | MLNRMGLL | |
| SCHEMBL3559161 | 0.90 | MLNR (0.70) | MLNRMGLLWNK1KMT2ANAAA | |
| SCHEMBL2766641 | 0.90 | MLNR (0.74) | MLNRMGLL | |
| SCHEMBL5114320 | 0.90 | MLNR (0.74) | MLNRMGLL | |
| SCHEMBL5101569 | 0.87 | MLNR (0.76) | MLNRMGLL | |
| SCHEMBL2765877 | 0.87 | MLNR (0.76) | MLNRMGLL | |
| SCHEMBL2767033 | 0.86 | MLNR (1.00) | MLNR | |
| SCHEMBL2767809 | 0.85 | MLNR (0.56) | MLNRMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853218-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| EP-2041093-B1 | PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-20090192160-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192160-A1 | COMPOUNDS | GPR68, GPR88, GPBAR1 | MLNR 251/4885MGLL 1402/4885WNK1 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.